The Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee

Inclusion Criteria: * Female and male patients who aged 40 or more and agreement with written informed consent * Patients with osteoarthritis according to ACR criteria lasted for the past 3 months or more * Patients with Kellgren \& Lawrence grade Ⅱ\~Ⅲ on radiographs * Patients with 40mm or higher 100mm Pain VAS on screening and baseline visit (based on more painful knee) * Patients with Lequesne's index 5 or more on screening and baseline visit Exclusion Criteria: * Patients who had taken SYSADOA within the past 3 months (Imotun, diacerein, s-adenosyl-methionone, JOINS, glucosamine, chondroitin and any other cartilage protective agents determined by investigator) * Patients who experienced cartilage surgery within the past 5 years or arthroscope surgery within a year(one side or both) * Patients who were treated with joint space injection within the past 3 months * Patients who had taken NSAIDs including pain killers within 7 days (except, it is acceptable to enroll the study if the patients have wash out periods at least 7 days before randomization) * Patients with hypersensitivity or allergy to the study or rescue medicine or those who have medical history. * Patients with severe liver, kidney or cardiac diseases who are not acceptable for the study determined by investigator * Patients with active peptic ulcer or GI bleeding. * Pregnancy, nursing women or women of reproductive age who do not agree to the contraception. * Patients with abuse of alcohol, illegal drugs or drug dependency * Patients who were treated with another investigational product within the past 4 weeks * All other patients who are not acceptable for the study determined by investigator